Competitive Grants Program
Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest and sets timelines for review and approval. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP. The grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements.
Sign up to receive all grant announcements, including Request for Proposal (RFP) postings.
Sign Up for Alerts Details-
Title Grant Type Focus Area Country Application Due Date Real World Evidence on the Impact of Early and Appropriate Use of Aztreonam-Avibactam (ATM-AVI)Release Date:Research Inflammation & Immunology Brazil, Chile, India, Italy, South Africa, Spain, United Kingdom Guideline Concordant Care and New Data for Patients with MIBC through la/mUCEducation Oncology USA Clinical Research Studies of Atirmociclib in HR+/HER2- and/or HER2+ Breast CancerRelease Date:Research Oncology Australia, Brazil, Canada, China, France, Germany, Italy, Japan, Korea, Mexico, Spain, Taiwan, USA, United Kingdom Quality Improvement Interventions to Enhance the Care of Patients Infected by MBL-CRE or S. maltophiliaRelease Date:Quality Improvement Inflammation & Immunology Australia, Chile, India, Italy, Spain, United Kingdom Advancing Real-World Evidence in Idiopathic Inflammatory Myopathies Through a German Disease RegistryRelease Date:Research Inflammation & Immunology Germany Real-World Evidence on Clinical Outcomes with ATM-AVI in Adult Patients with Stenotrophomonas maltophilia InfectionsRelease Date:Research Inflammation & Immunology China Real-World Evidence on Clinical Outcomes with Aztreonam-Avibactam (ATM-AVI) in Adult Patients with Limited Treatment OptionsRelease Date:Research Inflammation & Immunology China Tissue Penetration and Correlation with Clinical Outcomes of ATM-AVI in Adult Patients with Limited Treatment OptionsRelease Date:Research Inflammation & Immunology China Advancing Multidisciplinary Care in HemophiliaRelease Date:Quality Improvement Rare Disease China BCMA BsAb Educational Initiatives in 2L+ Relapsed/Refractory Multiple MyelomaRelease Date:Education Oncology USA -
Title Grant Type Focus Area Country Application Due Date Innovative Digital Health Projects to increase the Quality of Life (QoL) of Multiple Myeloma (MM) patientsRelease Date:Quality Improvement Oncology Italy 2024 RD Global Monitoring anti-TFPI RESRelease Date:Research Rare Disease All Call for Independent Medical Education Grant Applications Oncology – Urothelial Carcinoma (UC)Education Oncology All Health Services Research to Improve Management of mBC Patients Treated with TucatinibRelease Date:Research Oncology All Addressing Multiple Myeloma Gaps in Care for Patients in Latin AmericaRelease Date:Partner: International Myeloma FoundationEducation Oncology Argentina, Brazil, Colombia, Mexico Providing Appropriate Medical Care for IBD PatientsRelease Date:Partner: Japanese Society for Inflammatory Bowel Disease (JSIBD)Quality Improvement Inflammation & Immunology Japan Management of Atopic Dermatitis / Alopecia AreataRelease Date:Education Inflammation & Immunology USA Improving the Care Process for Patients with Advanced Prostate CancerRelease Date:Partner: The American Urological Association Education and Research, Inc.; AstellasQuality Improvement Oncology USA Optimizing Care for patients with locally advanced or metastatic Urothelial Carcinoma (la/mUC)Release Date:Quality Improvement Oncology Canada Prospective Surveillance and Burden of Disease for RSV-Related Respiratory Tract Infections in Taiwanese Pediatric PopulationRelease Date:Research Vaccines Taiwan PARP-Inhibitor Combination Therapies: Personalized Treatment for Patients with Metastatic Castration-Resistant Prostate CancerRelease Date:Education Oncology Canada Developing Educational Initiatives for ALK+ Metastatic Non-small Cell Lung Cancer Tyrosine Kinase Inhibitors TherapyRelease Date:Education Oncology Canada